Sugi Predict

Sugi Predict / Compounds / SCHEMBL1978901

SCHEMBL1978901

SCHEMBL1978901

Cc1cccc(Oc2ccc(N)cc2)c1C

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHFR P00374 1/20 0.62
▸ KEAP1 Q14145 1/20 0.58
▸ ALDH1A1 P00352 9/20 0.50
▸ TEAD4 Q15561 1/20 0.50
▸ NCOA1 Q15788 1/20 0.49
▸ NCOA3 Q9Y6Q9 1/20 0.49
▸ MAPT P10636 5/20 0.48
▸ SMN1; SMN2 Q16637 4/20 0.48
▸ TDP1 Q9NUW8 2/20 0.48
▸ POLB P06746 2/20 0.48
▸ GAA P10253 2/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ KMT2A Q03164 2/20 0.48
▸ MITF O75030 1/20 0.48
▸ GFER P55789 1/20 0.48
▸ NLRP1 Q9C000 1/20 0.48
▸ NOD2 Q9HC29 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ TSHR P16473 1/20 0.48
▸ CRHBP P24387 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21612720 0.92 ALDH1A1 (0.65) DHFRKEAP1ALDH1A1TEAD4NCOA1
SCHEMBL20854306 0.90 TEAD4 (0.56) DHFRKEAP1ALDH1A1TEAD4NCOA1
SCHEMBL24576257 0.90 DHFR (0.62) DHFRKEAP1ALDH1A1MAPTSMN1; SMN2
SCHEMBL22830371 0.85 ALDH1A1 (0.50) DHFRKEAP1ALDH1A1TEAD4NCOA1
SCHEMBL29553309 0.84 ALDH1A1 (0.60) DHFRALDH1A1TEAD4NCOA1NCOA3
SCHEMBL11585245 0.84 DHFR (0.57) DHFRKEAP1ALDH1A1TEAD4MAPT
SCHEMBL554682 0.84 ALDH1A1 (0.60) DHFRALDH1A1TEAD4NCOA1NCOA3
SCHEMBL2339526 0.82 DHFR (0.54) DHFRKEAP1ALDH1A1MAPTPOLB
SCHEMBL30358266 0.82 DHFR (0.54) DHFRKEAP1ALDH1A1MAPTPOLB
SCHEMBL1584959 0.81 TEAD4 (0.52) DHFRKEAP1ALDH1A1TEAD4NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11289238-B2 Compositions for the filling of high aspect ratio vertical interconnect access (VIA) holes HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) 2022-03-29 — — US disclosed
US-11180461-B2 Triazoles as Kv3 inhibitors AUTIFONY THERAPEUTICS LIMITED (GB) 2021-11-23 — — US disclosed
WO-2021112933-A1 COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC (US) 2021-06-10 — — WO disclosed
US-20210174983-A1 COMPOSITIONS FOR THE FILLING OF HIGH ASPECT RATIO VERTICAL INTERCONNECT ACCESS (VIA) HOLES HERAEUS PRECIOUS METALS NORTH AMERICA CONSHOHOCKEN LLC 2021-06-10 — — US disclosed
EP-2852589-B1 TRIAZOLES AS KV3 INHIBITORS AUTIFONY THERAPEUTICS LTD (GB) 2021-04-28 — — EP disclosed
US-20200172496-A1 TRIAZOLES AS KV3 INHIBITORS AUTIFONY SRL (IT) 2020-06-04 — — US disclosed
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 — — US disclosed
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 — — US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 — — US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 — — US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 — — EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 — — WO disclosed
US-6573278-B2 For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma BAYER AKTIENGESELLSCHAFT (DE) 2003-06-03 — — US disclosed
EP-0966436-B1 ARYL SULFONAMIDES AND ANALOGUES THEREOF AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES BAYER AG (DE) 2002-12-11 — — EP disclosed
US-20020072529-A1 Arylsulfonamides and analogues BAYER INTELLECTUAL PROPERTY GMBH (DE) 2002-06-13 — — US disclosed
US-6262112-B1 1-(4,4,4-TRIFLUOROBUTYLSULPHONYLOXY)-3-(2-(HYDROXYMETHYL)INDAN -4-YLOXY)-BENZENE BAYER AKTIENGESELLSCHAFT (DE) 2001-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 DHFR 3996/4885KEAP1 3193/4885ALDH1A1 848/4885
US-20200172496-A1 TRIAZOLES AS KV3 INHIBITORS KCNA3, KCNN3, KCNK3 DHFR 3381/4885KEAP1 1251/4885ALDH1A1 2268/4885
US-11180461-B2 Triazoles as Kv3 inhibitors KCNA3, KCNN3, KCNK3 DHFR 3381/4885KEAP1 1251/4885ALDH1A1 2268/4885
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 DHFR 3996/4885KEAP1 3193/4885ALDH1A1 848/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 DHFR 4077/4885KEAP1 2956/4885ALDH1A1 462/4885
US-20020072529-A1 Arylsulfonamides and analogues ARSA, PRSS12, SNCA DHFR 670/4885KEAP1 235/4885ALDH1A1 3020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.